Alector, Inc. Prices $75 Million Common Stock Offering to Fund Neurodegeneration Pipeline

Key numbers

Deal value	$75M
Share of market cap	36.5%

Key highlights

• Public offering of 36,600,000 shares priced at $2.05 per share
• Total gross proceeds of $75,030,000 before underwriting discounts
• Participation from institutional investors including TCGX and BVF Partners
• Offering price represents a 7.3 percent premium over the previous closing price
• Closing of the transaction is scheduled for October 19, 2026

What Is the Capital Raise?

Alector, Inc. has finalized an underwriting agreement with Morgan Stanley and Co. LLC and BTIG, LLC to issue 36.6 million shares of common stock. The shares are priced at $2.05 each, representing a 7.3 percent premium over the closing price on October 15, 2026. This registered public offering is expected to generate approximately $75.03 million in gross proceeds. The transaction involves significant participation from institutional investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. The offering is conducted under an existing shelf registration statement and is scheduled to close on or about October 19, 2026, subject to customary conditions.

Use of Proceeds

• Advancement of clinical research and development for neurodegeneration product candidates
• Scaling of manufacturing processes for therapeutic pipeline programs
• Funding general corporate purposes and working capital requirements
• Support for potential acquisitions of complementary biotechnology products
• Execution of strategic transactions in related technology or business sectors

Strategic Rationale

This capital raise follows a major milestone in October 2026, when Alector received a $100 million upfront payment from a global licensing deal with Genentech. The additional $75 million provides the company with further financial flexibility as it approaches key regulatory hurdles, including the planned Investigational New Drug application for AL137 in early 2027. Management previously guided that its cash position would extend the company's operational runway into 2029. By securing institutional backing from specialized healthcare funds, Alector bolsters its balance sheet to sustain long-term clinical trials for Alzheimer's and Parkinson's disease treatments while maintaining its proprietary blood-brain barrier platform development.

Business Overview

Based in South San Francisco, Alector is a clinical-stage biotechnology firm focused on immuno-neurology. The company’s research focuses on the immune system's role in neurodegeneration, aiming to restore nerve cell function and remove toxic proteins. Its portfolio includes programs targeting Alzheimer’s disease and other rare forms of dementia. Alector is also developing the Alector Brain Carrier, a proprietary blood-brain barrier technology designed to enhance the delivery of therapeutics into the central nervous system. This platform is intended to improve drug penetration and efficacy at lower doses, potentially reducing treatment costs and improving patient outcomes in complex neurological indications.

Alector, Inc. · financial snapshot

Share price	$1.84
Market cap	$205M
Revenue (annual)	$21M
1-month price change	-4.42%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.